Mesoblast Financial Results and Corporate Update Webcast
Mesoblast (NASDAQ:MESO), a global leader in allogeneic cellular medicines for inflammatory diseases, has announced a webcast to discuss their full-year financial results and operational highlights for the period ending June 30, 2025.
The webcast is scheduled for Thursday, August 28 at 6:30 PM EDT (Friday, August 29, 8:30 AM AEST). Investors can access the webcast through the company's provided link, and a recording will be available on Mesoblast's investor relations webpage.
Mesoblast (NASDAQ:MESO), azienda leader globale nelle terapie cellulari allogeniche per le malattie infiammatorie, ha annunciato un webcast per illustrare i risultati finanziari annuali e i principali sviluppi operativi relativi al periodo terminato il 30 giugno 2025.
Il webcast si terrà giovedì 28 agosto alle 18:30 EDT (venerdì 29 agosto, 08:30 AEST). Gli investitori potranno seguire il webcast tramite il link fornito dalla società; la registrazione sarà poi disponibile nella sezione investor relations del sito di Mesoblast.
Mesoblast (NASDAQ:MESO), líder mundial en terapias celulares alogénicas para enfermedades inflamatorias, ha anunciado un webcast para comentar sus resultados financieros anuales y los principales hitos operativos del periodo finalizado el 30 de junio de 2025.
El webcast está programado para el jueves 28 de agosto a las 18:30 EDT (viernes 29 de agosto, 08:30 AEST). Los inversores podrán acceder al webcast mediante el enlace facilitado por la compañía; la grabación quedará disponible en la página de relaciones con inversores de Mesoblast.
Mesoblast (NASDAQ:MESO), 염증성 질환을 위한 동종 세포치료제 분야의 글로벌 선도기업이 2025년 6월 30일로 마감된 기간의 연간 재무 실적 및 운영 하이라이트를 논의하는 웨비캐스트를 발표했습니다.
웨비캐스트는 8월 28일 목요일 오후 6:30 EDT에 예정되어 있으며 (8월 29일 금요일 오전 8:30 AEST), 투자자들은 회사가 제공한 링크를 통해 참여할 수 있습니다. 녹화본은 Mesoblast의 투자자 관계 웹페이지에 게시될 예정입니다.
Mesoblast (NASDAQ:MESO), leader mondial des traitements cellulaires allogéniques pour les maladies inflammatoires, a annoncé un webcast pour présenter ses résultats financiers annuels et les principaux faits marquants opérationnels pour la période clôturée le 30 juin 2025.
Le webcast est prévu le jeudi 28 août à 18h30 EDT (vendredi 29 août, 08h30 AEST). Les investisseurs pourront accéder au webcast via le lien fourni par la société ; un enregistrement sera disponible sur la page relations investisseurs de Mesoblast.
Mesoblast (NASDAQ:MESO), ein weltweit führendes Unternehmen für allogene Zelltherapien bei entzündlichen Erkrankungen, hat einen Webcast angekündigt, in dem die Jahresfinanzergebnisse und die wichtigsten operativen Entwicklungen für den zum 30. Juni 2025 endenden Zeitraum erläutert werden.
Der Webcast findet statt am Donnerstag, 28. August um 18:30 Uhr EDT (Freitag, 29. August, 08:30 Uhr AEST). Anleger können über den von der Gesellschaft bereitgestellten Link teilnehmen; eine Aufzeichnung wird auf der Investor-Relations-Seite von Mesoblast verfügbar sein.
- None.
- None.
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2025.
The webcast will begin at 6.30pm EDT, Thursday, August 28; 8.30am AEST, Friday, August 29, 2025. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2025/
The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | |
| Allison Worldwide | |
| Emma Neal | |
| T: +1 603 545 4843 | |
| E: emma.neal@allisonworldwide.com | |
| Media – Australia | |
| BlueDot Media | |
| Steve Dabkowski | |
| T: +61 419 880 486 | |
| E: steve@bluedot.net.au |
FAQ
When is Mesoblast's (MESO) FY2025 earnings webcast?
How can investors access Mesoblast's (MESO) FY2025 earnings webcast?
What will be discussed in Mesoblast's (MESO) upcoming webcast?
What is Mesoblast's (MESO) main business focus?
